Cited 496 times in
Ixabepilone Plus Capecitabine for Metastatic Breast Cancer Progressing After Anthracycline and Taxane Treatment
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 정현철 | - |
dc.date.accessioned | 2014-12-21T16:44:47Z | - |
dc.date.available | 2014-12-21T16:44:47Z | - |
dc.date.issued | 2007 | - |
dc.identifier.issn | 0732-183X | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/96274 | - |
dc.description.abstract | PURPOSE: Effective treatment options for patients with metastatic breast cancer resistant to anthracyclines and taxanes are limited. Ixabepilone has single-agent activity in these patients and has demonstrated synergy with capecitabine in this setting. This study was designed to compare ixabepilone plus capecitabine versus capecitabine alone in anthracycline-pretreated or -resistant and taxane-resistant locally advanced or metastatic breast cancer. PATIENTS AND METHODS: Seven hundred fifty-two patients were randomly assigned to ixabepilone 40 mg/m(2) intravenously on day 1 of a 21-day cycle plus capecitabine 2,000 mg/m(2) orally on days 1 through 14 of a 21-day cycle, or capecitabine alone 2,500 mg/m(2) on the same schedule, in this international phase III study. The primary end point was progression-free survival evaluated by blinded independent review. RESULTS: Ixabepilone plus capecitabine prolonged progression-free survival relative to capecitabine (median, 5.8 v 4.2 months), with a 25% reduction in the estimated risk of disease progression (hazard ratio, 0.75; 95% CI, 0.64 to 0.88; P = .0003). Objective response rate was also increased (35% v 14%; P < .0001). Grade 3/4 treatment-related sensory neuropathy (21% v 0%), fatigue (9% v 3%), and neutropenia (68% v 11%) were more frequent with combination therapy, as was the rate of death as a result of toxicity (3% v 1%, with patients with liver dysfunction [>/= grade 2 liver function tests] at greater risk). Capecitabine-related toxicities were similar for both treatment groups. CONCLUSION: Ixabepilone plus capecitabine demonstrates superior efficacy to capecitabine alone in patients with metastatic breast cancer pretreated or resistant to anthracyclines and resistant to taxanes. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 5210~5217 | - |
dc.relation.isPartOf | JOURNAL OF CLINICAL ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Anthracyclines/therapeutic use | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/therapeutic use* | - |
dc.subject.MESH | Breast Neoplasms/drug therapy* | - |
dc.subject.MESH | Breast Neoplasms/mortality | - |
dc.subject.MESH | Bridged-Ring Compounds/therapeutic use | - |
dc.subject.MESH | Capecitabine | - |
dc.subject.MESH | Deoxycytidine/administration & dosage | - |
dc.subject.MESH | Deoxycytidine/adverse effects | - |
dc.subject.MESH | Deoxycytidine/analogs & derivatives* | - |
dc.subject.MESH | Disease Progression | - |
dc.subject.MESH | Epothilones/administration & dosage* | - |
dc.subject.MESH | Epothilones/adverse effects | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Fluorouracil/administration & dosage | - |
dc.subject.MESH | Fluorouracil/adverse effects | - |
dc.subject.MESH | Fluorouracil/analogs & derivatives* | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Neoplasm Metastasis | - |
dc.subject.MESH | Taxoids/therapeutic use | - |
dc.title | Ixabepilone Plus Capecitabine for Metastatic Breast Cancer Progressing After Anthracycline and Taxane Treatment | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Eva S. Thomas | - |
dc.contributor.googleauthor | Henry L. Gomez | - |
dc.contributor.googleauthor | Henri H. Roché | - |
dc.contributor.googleauthor | Linda T. Vahdat | - |
dc.contributor.googleauthor | Pralay Mukhopadhyay | - |
dc.contributor.googleauthor | Ronald A. Peck | - |
dc.contributor.googleauthor | Guillermo L. Lerzo | - |
dc.contributor.googleauthor | Mario Campone | - |
dc.contributor.googleauthor | Binghe Xu | - |
dc.contributor.googleauthor | Fernando Hurtado de Mendoza | - |
dc.contributor.googleauthor | Judith V. Klimovsky | - |
dc.contributor.googleauthor | Xavier B. Pivot | - |
dc.contributor.googleauthor | Jacek Jassem | - |
dc.contributor.googleauthor | Valorie F. Chan | - |
dc.contributor.googleauthor | Luis E. Fein | - |
dc.contributor.googleauthor | Hyun-Cheol Chung | - |
dc.contributor.googleauthor | Rubi K. Li | - |
dc.identifier.doi | 10.1200/JCO.2007.12.6557 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A03773 | - |
dc.relation.journalcode | J01331 | - |
dc.identifier.eissn | 1527-7755 | - |
dc.identifier.pmid | 17968020 | - |
dc.identifier.url | http://jco.ascopubs.org/content/25/33/5210.long | - |
dc.contributor.alternativeName | Chung, Hyun Cheol | - |
dc.contributor.affiliatedAuthor | Chung, Hyun Cheol | - |
dc.rights.accessRights | not free | - |
dc.citation.volume | 25 | - |
dc.citation.number | 33 | - |
dc.citation.startPage | 5210 | - |
dc.citation.endPage | 5217 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CLINICAL ONCOLOGY, Vol.25(33) : 5210-5217, 2007 | - |
dc.identifier.rimsid | 35026 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.